Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline
Ricarda Stella Guninski, Francesco Cuccia, Filippo Alongi, Nicolaus Andratschke, Claus Belka, David Bellut, Max Dahele, Mirjana Josipović, T.E. Kroese, Pietro Mancosu, Giuseppe Minniti, Maximilian Niyazi, Umberto Ricardi, Per Munck af Rosenschöld, Arjun Sahgal, Y. Tsang, W.F.A.R. Verbakel, Matthias Gückenberger
Abstract
Background and purposeAdvances in characterizing cancer biology and the growing availability of novel targeted agents and immune therapeutics have significantly changed the prognosis of many patients with metastatic disease. Palliative radiotherapy needs to adapt to these developments. In this study, we summarize the available evidence for stereotactic body radiotherapy (SBRT) in the treatment of spinal metastases.Materials and methodsA systematic review and meta-analysis was performed using PRISMA methodology, including publications from January 2005 to September 2021, with the exception of the randomized phase III trial RTOG-0631 which was added in April 2023. Re-irradiation was excluded. For meta-analysis, a random-effects model was used to pool the data. Heterogeneity was assessed with the I2-test, assuming substantial and considerable as I2>50% and I2>75%, respectively. A p-value <0.05 was considered statistically significant.ResultsA total of 69 studies assessing the outcomes of 7236 metastases in 5736 patients were analyzed. SBRT for spine metastases showed high efficacy, with a pooled overall pain response rate of 83% (95% confidence interval [CI] 68%-94%), pooled complete pain response of 36% (95% CI: 20%-53%), and 1-year local control rate of 94% (95% CI: 86%-99%), although with high levels of heterogeneity among studies (I2=93%, I2=86%, and 86%, respectively). Furthermore, SBRT was safe, with a pooled vertebral fracture rate of 9% (95% CI: 4%-16%, pooled radiation induced myelopathy rate of 0% (95% CI 0-2%), and pooled pain flare rate of 6% (95% CI: 3%-17%), although with mixed levels of heterogeneity among the studies (I2=92%, I2=0%, and 95%, respectively). Only 1.7% of vertebral fractures required surgical stabilization.ConclusionSpine SBRT is characterized by a favorable efficacy and safety profile, providing durable results for pain control and disease control, which is particularly relevant for oligometastatic patients.